Lucid Diagnostics (NASDAQ:LUCD) Price Target Raised to $7.50 at Ascendiant Capital Markets
Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) had its price objective upped by investment analysts at Ascendiant Capital Markets from $7.00 to $7.50 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target points to a potential upside of 485.94% from […]
Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) had its price objective upped by investment analysts at Ascendiant Capital Markets from $7.00 to $7.50 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target points to a potential upside of 485.94% from […]
